Report Summary 1. Report Industry Investment Rating - Not provided in the given content 2. Core View of the Report - The futures index shows an oscillating pattern, suggesting an interval trading approach [3] 3. Summary by Relevant Catalogs a. Futures Index Data Tracking - On May 22, 2025, the closing prices of the four major futures index contracts showed mixed trends: IF fell 0.05%, IH rose 0.1%, IC fell 0.7%, and IM fell 0.81% [1] - In terms of trading volume, the total trading volume of futures indices rebounded, with IF's total trading volume decreasing by 5,644 lots, IH's increasing by 964 lots, IC's increasing by 18,347 lots, and IM's increasing by 52,241 lots [2] - Regarding positions, IF's total positions decreased by 1,805 lots, IH's increased by 817 lots, IC's increased by 7,568 lots, and IM's increased by 23,866 lots [2] b. Basis - Basis data for IF, IH, IC, and IM are presented in graphical form, showing the basis trends of the current month, next month, current quarter, and next quarter contracts over a period [4] c. Positions of the Top 20 Futures Members - For IF contracts, the long - positions of IF2506 decreased by 2,557 lots, IF2509 increased by 335 lots, and IF2512 decreased by 22 lots; the short - positions of IF2506 decreased by 2,713 lots, IF2509 increased by 78 lots, and IF2512 increased by 37 lots [5] - For IH contracts, the long - positions of IH2506 increased by 875 lots, IH2509 increased by 143 lots; the short - positions of IH2506 decreased by 68 lots, IH2509 increased by 205 lots [5] - For IC contracts, the long - positions of IC2506 increased by 3,227 lots, IC2509 increased by 788 lots, and IC2512 increased by 1,028 lots; the short - positions of IC2506 increased by 2,927 lots, IC2509 increased by 780 lots, and IC2512 increased by 1,500 lots [5] - For IM contracts, the long - positions of IM2506 increased by 11,520 lots, IM2509 increased by 3,538 lots; the short - positions of IM2506 increased by 11,222 lots, IM2509 increased by 3,445 lots [5] d. Trend Intensity - The trend intensity of IF and IH is 1, and that of IC and IM is also 1, with the trend intensity ranging from - 2 to 2, where - 2 is the most bearish and 2 is the most bullish [6] e. Important Drivers - The selling of US Treasuries has temporarily paused, the Nasdaq has rebounded with difficulty, the tax - cut bill has hit photovoltaic stocks, Bitcoin has reached a new high again during the session, and crude oil has fallen by more than 2% [6] - Fed Governor Waller said that the tax - cut bill triggered the selling of US Treasuries, and if the tariff policy stabilizes around 10%, the Fed may cut interest rates in the second half of 2025 [6] f. A - share Market Summary - On the day, the Shanghai Composite Index closed down 0.22% at 3,380.19 points, the Shenzhen Component Index fell 0.72%, the ChiNext Index fell 0.96%, the North - bound 50 Index fell 6.15%, the Science and Technology Innovation 50 Index fell 0.48%, the Wind All - A Index fell 0.63%, the Wind A500 Index fell 0.28%, and the CSI A500 Index fell 0.3% [7] - A - share trading volume was 1.14 trillion yuan, down from 1.21 trillion yuan the previous day [7] - Military stocks led the gains, with Guoke Tiancheng and Sichuang Electronics hitting the daily limit; innovative drug concept stocks were active, with Sansheng Guojian having four consecutive daily limits; bank stocks bucked the trend and strengthened, with many stocks such as Everbright Bank and China CITIC Bank reaching new highs; pet economy concept stocks led the decline, with Yuanfei Pet hitting the daily limit down; beauty care concept stocks tumbled, with Marubi and Jieya Co., Ltd. falling more than 8%; solid - state battery concept stocks retreated, with many stocks falling more than 5% [7]

证券代码：603983 证券简称：丸美生物 公告编号：2025-015 广东丸美生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年5月22日 (二)股东大会召开的地点：广州天河区珠江新城冼村路11号保利威座大厦南塔6楼丸美生物会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 审议结果：通过 ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，采用现场投票与网络投票相结合的方式召开。因董事长孙怀庆出差在外不 能现场主持本次股东大会，半数以上董事推选董事王开慧先生主持本次股东大会。会议的召集和召开程 序、出席会议人员的资格、会议的表决方式与程序均符合《公司法》《上市公司股东会规则》及《公司 章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人，董事长孙怀庆 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-015 广东丸美生物技术股份有限公司 2024年年度股东大会决议公告 (一)股东大会召开的时间：2025 年 5 月 22 日 (二)股东大会召开的地点：广州天河区珠江新城冼村路 11 号保利威座大厦南塔 6 楼丸美生物会议室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 122 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 336,471,849 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 83.9081 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，采用现场投票与网络投票相结合的方式召开。 因董事长孙怀庆出差在外不能现场主持本次股东大会，半数以上董事推选董事王 开慧先生主持本次股东大会。会议的召集和召 ...

广东信达律师事务所 股东大会法律意见书 中国 深圳 福田区 益田路 6001 号 太平金融大厦 11、12 楼 邮政编码：518038 11F/12F., TAIPING FINANCE TOWER, NO.6001 YITIAN ROAD, SHENZHEN, CHINA 电话（Tel.）：（0755）88265288 传真（Fax.）：（0755）88265537 网站（Website）：https://www.sundiallawfirm.com 广东信达律师事务所 关于广东丸美生物技术股份有限公司 2024 年年度股东大会的 法律意见书 信达会字（2025）第 177 号 致：广东丸美生物技术股份有限公司 广东信达律师事务所（以下简称"信达"）接受广东丸美生物技术股份有限 公司（下称"贵公司"）的委托，指派律师参加了贵公司 2024 年年度股东大会 （下称"本次股东大会"），并进行了必要的验证工作。现根据《中华人民共和 国公司法》（下称"《公司法》"）、《上市公司股东会规则》（下称"《股东 会规则》"）以及贵公司《公司章程》的规定，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东大会的 ...

Core Insights - The free short drama market is rapidly encroaching on the short drama market share, prompting many mid-tier teams to pivot towards free and branded short dramas [1][3] - DataEye's observation indicates that brand-customized short dramas have seen an increase in promotional efforts, with 92 new brand short dramas launched in March and April 2025, showing slight growth compared to the previous year [1][4] Data Overview - A total of 129 new brands entered the short drama space in 2025, with 84 brands joining in January alone, indicating a crowded competitive landscape [4] - The top-performing brand short dramas since April include "Dear Enemy" with 280 million views, "Secret Crush Can't Be Hidden" with 160 million views, and "Chasing Light" with 140 million views [5][9] Brand Performance - Among the top 10 brand-customized short dramas, Meituan's group buying service accounted for 50% of the total, with two of the top three dramas produced by Meituan [7][10] - The interactive engagement for "Hello, Classmate Mom" produced by Marubi reached over 2 million likes, indicating strong audience interaction [12][14] Market Dynamics - The short drama market is experiencing a polarization, with some brand short dramas failing to meet promotional expectations, while others successfully cultivate brand image and value through storytelling [22][24] - The total consumption of the domestic micro-short drama market reached 6.67 billion in Q1 2025, reflecting a 3% decrease from Q4 2024, as free platforms like Hongguo and Hemajuchang continue to erode the paid market [18][21] Content Strategy - Successful brand short dramas combine classic themes with current social issues, enhancing viewer engagement and brand recognition [28][30] - Meituan's short dramas effectively integrate brand messaging within the narrative, using dynamic geographic targeting to connect viewers with nearby services [34][36] Promotional Tactics - Meituan's promotional strategies are tailored to different platforms, leveraging Douyin for topic creation and Kuaishou for conversion, creating a comprehensive marketing matrix [40][41] - The brand's short dramas are designed to facilitate seamless transitions from content viewing to consumer action, enhancing overall effectiveness [33][39]

Group 1 - The recombinant protein concept sector rose by 2.52%, ranking second among concept sectors, with 30 stocks increasing in value [1][2] - Notable gainers included Sangon Biotech, which hit the daily limit with a 20% increase, and other significant performers such as Sai Sheng Pharmaceutical, Jie Ya Co., and Jinbo Bio, which rose by 16.37%, 9.31%, and 9.17% respectively [1][2] - The sector experienced a net inflow of 221 million yuan from main funds, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Leading the net inflow was Xilong Scientific, which saw a net inflow of 242 million yuan, followed by Rejuve Pharmaceutical and Zexin Pharmaceutical with net inflows of 37.78 million yuan and 32.48 million yuan respectively [2][3] - The top three stocks by net inflow ratio were Xilong Scientific at 20.85%, Zexin Pharmaceutical at 8.53%, and Chengdu Xian Dao at 7.96% [3][4] - Stocks with notable declines included Furuida, Zhongyuan Xiehe, and Wanmei Biological, which fell by 2.25%, 1.92%, and 1.80% respectively [1][5]

Summary of Marubi Biotech Conference Call Company Overview - **Company**: Marubi Biotech - **Industry**: Beauty and Health Key Points and Arguments Financial Performance and Strategy - Marubi Biotech has improved its gross margin significantly by streamlining SKUs and implementing a big product strategy, particularly with the Xiaohongbi and Xiaojin series. The supply chain turnover period has been reduced from 90 days to approximately 40 days, enhancing operational efficiency. The additional profits will be reinvested into market sales expenses [2][5][6]. - In 2024, the online GMV for Xiaohongbi reached 530 million yuan, nearly doubling year-on-year, accounting for about 25% of the main brand. The Xiaojin series also saw a growth rate of approximately 90%. The company aims for at least a 50% growth in these two major products by 2025, with expectations for Xiaojin cream and Super Mask to achieve sales in the hundreds of millions [2][7][12]. Sales Channels and Marketing - Marubi's sales on content e-commerce platforms like Douyin and Kuaishou account for over 40%, with Tmall around 30% and Vipshop about 20%. The remaining sales are distributed across platforms like JD and Pinduoduo, with net profit levels across channels being relatively similar [2][15]. - The company has shifted its marketing strategy to focus on long-term growth rather than short-term sales spikes, with a series of marketing activities planned leading up to major sales events like 618 [3][12]. Product Development and Innovation - Marubi is actively expanding its product lines in the beauty and health sectors, including functional skincare brands and oral care products. The company has also invested in medical beauty projects, such as Shuangmei Biotech [2][20][21]. - The company has established a dual beauty strategy combining lifestyle beauty and medical beauty, with expectations for significant results in the medical beauty sector within three years [5][22]. Supply Chain and Operational Efficiency - The company has implemented measures to enhance supply chain efficiency, particularly in transitioning from a B2B to a B2C model, requiring faster delivery times and improved product variety [6][7]. - The integration of front, middle, and back-end management has led to significant improvements in operational speed and gross margin [6][7]. Market Trends and Consumer Behavior - The beauty market is experiencing structural changes, with a trend towards younger consumers and a shift in purchasing habits. The company aims to attract younger demographics to build brand loyalty [14][26]. - The competition in the beauty industry is intense, with a focus on product quality, content, and operational capabilities being crucial for success [29]. Future Outlook - 2025 is considered a pivotal year for Marubi, as the company aims to maintain its growth trajectory amidst increasing market competition. The company has set a three-year goal to validate its online transformation success [25][33]. - The company is also exploring opportunities for external investments and brand acquisitions, although current growth from existing brands is deemed sufficient for the near future [23][24]. Additional Important Insights - The company has a robust technical research system, particularly in collagen technology, which supports its product development and market competitiveness [22][30]. - Marubi's non-main business income primarily comes from investment subsidies and returns, indicating a diversified revenue stream [18]. This summary encapsulates the key insights from the conference call, highlighting Marubi Biotech's strategic initiatives, market positioning, and future growth plans.

Group 1 - The A-share market saw all three major indices rise, with the beauty and personal care sector continuing its strong performance, leading the industry indices with a 2.5% increase [1] - Since early April, the beauty and personal care industry index has accumulated a nearly 25% increase, making it the top performer among all 31 Shenwan first-level industry indices, with a year-to-date increase of 17.3%, outperforming the second-place automotive industry index by 4.6 percentage points [3][5] - The beauty and personal care industry is experiencing stable growth driven by continuous policy benefits, consumption recovery, and escalating trade tensions, with domestic brands gaining market share due to high cost-performance and refined operations [5] Group 2 - The recent 2025 Shanghai Beauty Expo introduced new products from listed companies like Proya and Fulejia, further boosting the beauty and personal care sector's momentum [6] - The stock with the highest increase in the beauty and personal care industry index this year is Lafang Jiahua, which has surged 98.62%, while other companies like Runben, Dengkang, Marubi, Haoyue, Qingdao King, and Shanghai Jahwa have also seen increases exceeding 50% [6] - Despite being the largest company by market capitalization in the industry, Aimeike has seen a year-to-date decline of 0.87%, with its first-quarter revenue and net profit showing negative growth for the first time since its listing, and its gross margin dropping to a record low of 93.85% [6]

Core Viewpoint - The announcement of the change in fund manager for "Yongying Hong Kong Stock Connect Quality Life Selected Mixed Fund" from Yan Qing to Jiang Weihua highlights a significant shift in management, with implications for fund performance and investor confidence [1][4]. Group 1: Fund Manager Change - Yan Qing, an experienced investment manager with 19 years in the securities industry, has stepped down from managing the largest fund under Yongying, which had a size of 619 million yuan as of March 31, 2025 [1][3]. - Jiang Weihua, who has only 1.81 years of experience as a fund manager, will take over the management of the fund, increasing his total managed assets to approximately 1.306 billion yuan [13][15]. Group 2: Fund Performance - The "Yongying Hong Kong Stock Connect Quality Life Selected Mixed Fund" has shown a year-to-date return of 9.99%, outperforming its benchmark of 9.94% and significantly surpassing the CSI 300 index's return of -1.47% [4][8]. - Despite the recent strong performance, the fund has underperformed its benchmark by 31.54% since inception, with a total return of -26.80% compared to the benchmark's 4.74% [6][8]. Group 3: Historical Performance Analysis - Yan Qing's management of the fund has been inconsistent, with annual returns showing significant underperformance against benchmarks in previous years, particularly from 2021 to 2024 [4][6]. - The fund's performance has raised concerns regarding the sustainability of returns, especially given the recent regulatory focus on long-term performance metrics for fund managers [4][6]. Group 4: Comparison of Fund Products - Jiang Weihua's other managed funds, such as "Yongying New Consumption Smart Selection," have shown strong performance with a year-to-date return of 20.41%, indicating a potential for better management outcomes [18][21]. - The divergence in performance between Jiang Weihua's funds suggests that stock selection and market conditions play a crucial role in fund performance, with specific stocks like Pop Mart and TCL Electronics contributing significantly to returns [21].

Group 1: Personal Care Industry - The personal care sector is experiencing growth driven by increased national income and health demands, providing opportunities for domestic brands to gain market share [1] - Douyin's channel is accelerating the online growth of personal care products, with GMV growth expected to reach 38.86% in 2024, significantly outpacing cosmetics [1] - Recommended stocks include companies with clear technological advantages and strong operational capabilities, such as Dengkang Oral Care and Runben Co., with a focus on brands that combine technological innovation and channel control [1] Group 2: Cosmetics Industry - The cosmetics industry saw an unexpected growth rate of 3.2% in Q1 2025, attributed to consumption promotion policies and a low base effect, entering a phase of normalized growth [2] - Foreign brands are facing dual pressures from tariffs and store closures, leading to a negative performance, while domestic brands are actively innovating and expanding their product lines [2] - Recommended stocks include Marubi and Proya, with a focus on companies that are actively innovating and showing strong performance [2] Group 3: Offline Beauty Care - The offline beauty care sector is experiencing a divided performance, driven by supply-side innovations, particularly in new materials like collagen and hydroxyapatite [3] - Companies like Jinbo Bio are leading in the field of recombinant collagen, with a rich product layout and capacity expansion plans [3] - The offline beauty care industry is expected to benefit from technological innovations and supportive consumption policies, with recommendations for Jinbo Bio and Juzhi Bio [3]